Nomura Holdings Inc. Sells 40,853 Shares of Integer Holdings Co. (NYSE:ITGR)

Nomura Holdings Inc. trimmed its position in shares of Integer Holdings Co. (NYSE:ITGR) by 22.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,417 shares of the medical equipment provider’s stock after selling 40,853 shares during the quarter. Nomura Holdings Inc. owned 0.42% of Integer worth $13,813,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Integer by 0.4% during the third quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider’s stock worth $301,484,000 after purchasing an additional 15,300 shares during the period. FMR LLC raised its position in shares of Integer by 12.8% during the third quarter. FMR LLC now owns 863,938 shares of the medical equipment provider’s stock worth $67,759,000 after purchasing an additional 97,851 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in Integer by 497.0% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 536,343 shares of the medical equipment provider’s stock valued at $42,065,000 after buying an additional 446,508 shares during the last quarter. abrdn plc raised its position in Integer by 0.6% in the 4th quarter. abrdn plc now owns 520,646 shares of the medical equipment provider’s stock valued at $51,586,000 after buying an additional 3,013 shares during the last quarter. Finally, Congress Asset Management Co. MA raised its position in Integer by 12.5% in the 4th quarter. Congress Asset Management Co. MA now owns 421,524 shares of the medical equipment provider’s stock valued at $41,765,000 after buying an additional 46,776 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Integer

In other news, EVP John A. Harris sold 1,521 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $120.44, for a total transaction of $183,189.24. Following the completion of the transaction, the executive vice president now owns 4,922 shares in the company, valued at approximately $592,805.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Integer news, EVP John A. Harris sold 312 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $113.00, for a total value of $35,256.00. Following the completion of the transaction, the executive vice president now owns 1,157 shares in the company, valued at approximately $130,741. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John A. Harris sold 1,521 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $120.44, for a total value of $183,189.24. Following the completion of the transaction, the executive vice president now owns 4,922 shares of the company’s stock, valued at approximately $592,805.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,936 shares of company stock worth $2,130,937. 2.00% of the stock is owned by company insiders.

Integer Stock Down 1.9 %

Shares of NYSE:ITGR opened at $115.03 on Wednesday. The company has a market capitalization of $3.85 billion, a PE ratio of 39.80, a price-to-earnings-growth ratio of 1.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.32 and a quick ratio of 2.01. The business has a fifty day moving average price of $117.24 and a two-hundred day moving average price of $109.05. Integer Holdings Co. has a 1 year low of $69.40 and a 1 year high of $123.99.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million during the quarter, compared to the consensus estimate of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 EPS. Analysts forecast that Integer Holdings Co. will post 5.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ITGR. Truist Financial began coverage on Integer in a research report on Wednesday, May 15th. They issued a “buy” rating and a $137.00 price target for the company. Citigroup increased their price target on Integer from $118.00 to $124.00 and gave the company a “neutral” rating in a research report on Wednesday, May 22nd. CL King began coverage on Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 price target for the company. Benchmark reissued a “buy” rating and issued a $130.00 price target on shares of Integer in a research report on Friday, May 10th. Finally, Bank of America raised Integer from a “neutral” rating to a “buy” rating and increased their price target for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Integer currently has an average rating of “Moderate Buy” and an average price target of $128.00.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.